Because early treatment choice is critical in first-episode schizophrenia-spectrum disorders
(FES), this meta-analysis compared efficacy and tolerability of individual second-generation …

Background. Existing outcome literature has had an over-representation of chronic patients
and suggested a progressive course and poor outcome for schizophrenia. The current study …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

Despite treatment advances over the past decades, schizophrenia remains one of the most
severe psychiatric disorders that is associated with a chronic relapsing course and marked …

Objective: The RAISE (Recovery After an Initial Schizophrenia Episode) Connection
Program Implementation and Evaluation Study developed tools necessary to implement and …

Objective: The majority of first-episode psychosis (FEP) patients reach clinical remission;
however, rates of relapse are high. This study sought to undertake a systematic review and …

Introduction: Glycogen synthase kinase 3 (GSK3) is at the center of cellular signaling and
controls various aspects of brain functions, including development of the nervous system …

Objectives Clinical practice guidelines (CPGs) support the translation of research evidence
into clinical practice. Key health questions in CPGs ensure that recommendations will be …

BackgroundThere is an ongoing debate about the use of atypical antipsychotics as a first-
line treatment for first-episode psychosis. AimsTo examine the evidence base for this …

The schizophrenia spectrum disorders are neurodevelopmental illnesses with a lifetime
prevalence near 1%, producing extensive functional impairment and low expectations for …